Leyden Labs, a Leiden, the Netherlands-based supplier of a mucosal safety platform, raised $70M in funding.
The spherical was led by ClavystBio and Polaris Companions with participation from Qiming Enterprise Companions and continued backing from current traders together with GV and Casdin Capital.
The corporate intends to make use of the funds to help additional improvement of its pipeline geared toward offering safety in opposition to respiratory viruses, resembling influenza and coronaviruses.
Led by CEO Koenraad Wiedhaup, Leyden Labs is leveraging its mucosal safety platform to develop a portfolio of candidates geared toward offering safety in opposition to influenza, coronaviruses, and different respiratory viruses by means of a brand new class of broadly protecting nasal sprays.
Along with this financing, the corporate introduced the acquisition of CoV Biotechnology Pte. Ltd., a Singapore-based biotech firm with belongings developed by Linfa Wang, a professor of rising infectious ailments at Duke-NUS Medical College.
FinSMEs
09/01/2025
